Your basket is currently empty!
Category: research
Artificial Identity
James DiGiovanna
DOI:10.1093/oso/9780190652951.003.0020
Enhancement and AI create moral dilemmas not envisaged in standard ethical theories. Some of this stems from the increased malleability of personal identity that this technology affords: an artificial being can instantly alter its memory, preferences, and moral character. If a self can, at will, jettison essential identity-giving characteristics, how are we to rely upon, befriend, or judge it? Moral problems will stem from the fact that such beings are para-persons: they meet all the standard requirements of personhood (self-awareness, agency, intentional states, second-order desires, etc.) but have an additional ability—the capacity for instant change—that disqualifies them from ordinary personal identity. In order to rescue some responsibility assignments for para-persons, a fine-grained analysis of responsibility-bearing parts of selves and the persistence conditions of these parts is proposed and recommended also for standard persons who undergo extreme change.
Genomic Surveillance
Executive summary
Genomic surveillance in Belgium is based on whole genome sequencing (WGS) of a selection of
representative samples, complemented with targeted active surveillance initiatives and targeted
molecular markers aiming to early detect and precisely monitor the epidemiological evolution of
variants of concern (VOCs). Currently, 5.050 sequences of samples collected in Belgium are available
on GISAID in open access. During week 3 of 2021, Belgium achieved a coverage of 3,5% of all positive
sequences being sequenced.
During the last 2 weeks (week 5 and 6), 146 samples have been sequenced as part of the baseline
surveillance, among which 48 (33%) were 501Y.V1 and 8 (5%) were 501Y.V2.
Since week 52 of 2020, Belgium has experienced multiple introductions of VOCs followed by sustained
local transmissions. As a consequence of a higher transmissibility of these variants, we observe a
progressive shift in viral populations, with 501Y.V1 expected to represent the majority of circulating
strains by early March. Together with the rollout of vaccination, genomic surveillance will monitor the
eventual positive selection of VOCs harbouring immune escape mutations such as S:E484K.
During the last 2 weeks, the progressive phenomenon of viral population replacement by more
transmissible strains did not alter the overall stability of the epidemic in Belgium. This is probably due
to a combination of active public health response and limited number of social interactions in the
population. The risk of disruption of this equilibrium remains, as the proportion of more transmissible
viruses will continue rising, but this risk can be mitigated by a combination of active outbreak control
interventions, maintained efforts to reduce transmission in the population and rapid roll-out of
vaccination.